抄録
The purpose of this paper is to clarify, for foreign and multinational medical companies, the success
factors for the Drug LCM (Life Cycle Management) strategy in the Japanese market. The LCM strategy in
this study means the strategy for appropriate extension of the product lifecycle including measures for
generic drug production.
This study examined the “strategy”, ”strategy organization”, and “practice process” in LCM of Pfizer,
AstraZeneca, Janssen, Sanofi, and MSD.
As a result, it was revealed that companies in this study increase product value by the addition of
dosage/capacity, indication, and combination agents through the LCM strategy. For strategic practice
process, it was suggested that Pfizer and Janssen take a Global Approach (centralized model) and
AstraZeneca, Sanofi, and MSD take a Trans-National Approach (decentralized and mutually dependent
model).
Strategy planning depending on the character of the Japanese market and an organization or process to
enable interdivisional cooperation and quick decision-making is required for the LCM strategy to succeed
in the Japanese market. To do this, a global viewpoint and high local adaptation are required.
Therefore, taking the Trans-National approach is desirable when foreign and multinational medical
companies carry out the LCM strategy in the Japanese market.
https://ror.org/00ntfnx83 
